MEDICAL IP gains FDA approval for DeepCatch AI software for whole-body composition CT quantification
MEDICAL IP, an AI-based digital twin company, has revealed its CT-based automatic body composition analysis AI software, DeepCatch, has received FDA 510(k) Clearance. DeepCatch is a SaMD (Software as Medical Device) that automatically segments and analyses anatomical structures in computed tomography (CT) scan and provides the results as a report with 3D visual and quantitative information. According to the company, DeepCatch is the only FDA cleared AI software that automatically analyses various body components such as skin, bone, muscle, visceral fat, subcutaneous fat, internal organ, and central nervous system through whole-body CT.
With the increasing importance of opportunistic screening, medical staffs will be able to provide additional screening for possible body composition-related diseases based on the DeepCatch report. Also, patients can obtain additional medical information about diseases such as obesity, metabolic diseases, sarcopenia, by using CT images taken during hospital treatment or health checkups. This makes it possible for anyone to manage their health efficiently and proactively.
A company official said, "DeepCatch has proven that it provides accurate body composition analysis results to anyone regardless of race, gender, or age. It will contribute to the development of the medical industry through fast, accurate, and efficient CT-based body composition analysis technology."
During the FDA Clearance process, DeepCatch was tested for bias of various CT scanners, medical institutions, race, and ethnicity in a series of multi-national clinical trials, including in the United States. As a result, the general-purpose performance and safety was confirmed through validation of the accuracy of AI-based analysis, including the measurement of the volume and area of body components and the body circumference.
Furthermore, unlike methods such as BIA (Bioelectrical Impedance Analysis), which are affected by the measurement environment or body condition, or DXA (Dual-Energy X-ray Absorptiometry) which cannot separately quantify areas such as visceral fat in three dimensions, DeepCatch can robustly derive clinically valid 3D body composition analysis results using CT. Therefore, it is expected to present a new standard for body composition.
In July of last year, CPT code was issued for quantitative CT tissue characterisation, including interpretation and report, obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging. Accordingly, this FDA Clearance will provide an opportunity for DeepCatch, which calculates body composition information from CT, to be quickly introduced to the medical field in the US.
"There are various diseases related to body composition, such as geriatric diseases, cardiovascular diseases, and metabolic diseases such as diabetes and sarcopenia in the elderly and cancer patients, and DeepCatch is a product that can provide additional clinical information on these diseases,” said MEDICAL IP CEO, Joon S Park. “DeepCatch can be introduced to any medical institution around the world that takes CT scans, so with this FDA Clearance, we will be able to accelerate our strategy for global expansion."